SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
Hart, S, Goh, K C, Novotny-Diermayr, V, Hu, C Y, Hentze, H, Tan, Y C, Madan, B, Amalini, C, Loh, Y K, Ong, L C, William, A D, Lee, A, Poulsen, A, Jayaraman, R, Ong, K H, Ethirajulu, K, Dymock, B W, Wood, J W
Published in Leukemia (01.11.2011)
Published in Leukemia (01.11.2011)
Get full text
Journal Article
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
Goh, K C, Novotny-Diermayr, V, Hart, S, Ong, L C, Loh, Y K, Cheong, A, Tan, Y C, Hu, C, Jayaraman, R, William, A D, Sun, E T, Dymock, B W, Ong, K H, Ethirajulu, K, Burrows, F, Wood, J M
Published in Leukemia (01.02.2012)
Published in Leukemia (01.02.2012)
Get full text
Journal Article
Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours
Tan, D., Ng, M., Subbiah, V., Messersmith, W., Teneggi, V., Diermayr, V., Ethirajulu, K., Yeo, P., Gan, B.H., Lee, L.H., Blanchard, S., Nellore, R., Yasin, M., Umrani, D., Lee, M.A., Hill, J., Madan, B., Virshup, D., Matter, A.
Published in Annals of oncology (01.11.2018)
Published in Annals of oncology (01.11.2018)
Get full text
Journal Article
The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
Novotny-Diermayr, V, Hart, S, Goh, K C, Cheong, A, Ong, L-C, Hentze, H, Pasha, M K, Jayaraman, R, Ethirajulu, K, Wood, J M
Published in Blood cancer journal (New York) (01.05.2012)
Published in Blood cancer journal (New York) (01.05.2012)
Get full text
Journal Article
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
Hart, S, Goh, K C, Novotny-Diermayr, V, Tan, Y C, Madan, B, Amalini, C, Ong, L C, Kheng, B, Cheong, A, Zhou, J, Chng, W J, Wood, J M
Published in Blood cancer journal (New York) (01.11.2011)
Published in Blood cancer journal (New York) (01.11.2011)
Get full text
Journal Article
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
Razak, A R A, Hotte, S J, Siu, L L, Chen, E X, Hirte, H W, Powers, J, Walsh, W, Stayner, L-A, Laughlin, A, Novotny-Diermayr, V, Zhu, J, Eisenhauer, E A
Published in British journal of cancer (01.03.2011)
Published in British journal of cancer (01.03.2011)
Get full text
Journal Article
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies
Yong, W.P., Goh, B.C., Soo, R.A., Toh, H.C., Ethirajulu, K., Wood, J., Novotny-Diermayr, V., Lee, S.C., Yeo, W.L., Chan, D., Lim, D., Seah, E., Lim, R., Zhu, J.
Published in Annals of oncology (01.11.2011)
Published in Annals of oncology (01.11.2011)
Get full text
Journal Article
416 The oral HDAC inhibitor SB939 shows activity in in vitro and in vivo models of acute myeloid leukemia
Diermayr, V, Ong, L.C, Loh, Y.K, Cheong, A, Hart, S, Goh, K.C, Hentze, H.H, Wang, H, Ethirajulu, K.E, Wood, J.M
Published in European journal of cancer supplements (2010)
Published in European journal of cancer supplements (2010)
Get full text
Journal Article
78 TG02, a multi-kinase inhibitor with potent single agent and chemosensitization activity against solid tumors
Burrows, F.J, Goh, K.C, Novotny-Diermayr, V, Hart, S, Tan, Y.C, Loh, Y.K, Cheatham, L.A, Meshaw, K.R, Zaknoen, S, Wood, J
Published in European journal of cancer supplements (2010)
Published in European journal of cancer supplements (2010)
Get full text
Journal Article
PP72 Demonstration of dose-dependent target inhibition using a quantitative biomarker assay for SB939, a potent, orally active HDAC inhibitor, in a Phase I clinical study in solid tumors
Novotny-Diermayr, V, Liang, A.-L, Loh, Y.K, Hentze, H, Jayaraman, R, Ethirajulu, K, Zhu, J, Wood, J.M
Published in European journal of cancer supplements (2009)
Published in European journal of cancer supplements (2009)
Get full text
Journal Article
653P A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors
Ng, M.C.H., Yong, W.P., Meric-Bernstam, F., Lentz, R.W., Srirangam, V., Cometa, J.R., Blanchard, S., Nellore, R., Tan, A., Lee, Y-A., Lim, J., Gan, S., Koh, C., Adanan, Q., Joy, J., Pendharkar, V., Yeong, J.P.S., Diermayr, V.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
83 POSTER A robust and quantitative biomarker assay for SB939, a potent, orally-active HDAC inhibitor
Novotny-Diermayr, V, Nayagam, V.M, Hentze, H.H, Liang, A.L, Loh, Y.K, Sausgruber, N, Yeo, P, Ethirajulu, K, Wood, J.M
Published in European journal of cancer supplements (2008)
Published in European journal of cancer supplements (2008)
Get full text
Journal Article
99P Development of a qRT-PCR-based diagnostic test to identify colorectal cancer patients with recurrent R-Spondin gene fusions
Diermayr, V., Sarma, S., Lee, K.F.Y., Ng, P., Tong, C.K., Soon, V., Gan, B.H., Qu, Z.J., Tan, Z., Han, X., Phua, L.Y., Poh, H.M., Gan, A., Camat, D.M., Weng, R., Cheong, E.W., Inoue, M., Lezhava, A., Tan, I.B., Lim, T.K.H.
Published in Annals of oncology (01.11.2020)
Published in Annals of oncology (01.11.2020)
Get full text
Journal Article
71OPhase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours
Tan, D, Ng, M, Subbiah, V, Messersmith, W, Teneggi, V, Diermayr, V, Ethirajulu, K, Yeo, P, Gan, B H, Lee, L H, Blanchard, S, Nellore, R, Yasin, M, Umrani, D, Lee, M A, Hill, J, Madan, B, Virshup, D, Matter, A
Published in Annals of oncology (01.11.2018)
Published in Annals of oncology (01.11.2018)
Get full text
Journal Article
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer
Novotny-Diermayr, Veronica, Sangthongpitag, Kanda, Hu, Chang Yong, Wu, Xiaofeng, Sausgruber, Nina, Yeo, Pauline, Greicius, Gediminas, Pettersson, Sven, Liang, Ai Leng, Loh, Yung Kiang, Bonday, Zahid, Goh, Kee Chuan, Hentze, Hannes, Hart, Stefan, Wang, Haishan, Ethirajulu, Kantharaj, Wood, Jeanette Marjorie
Published in Molecular cancer therapeutics (01.03.2010)
Published in Molecular cancer therapeutics (01.03.2010)
Get full text
Journal Article
152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours
Teneggi, V., Ng, M., Tan, D.S., Subbiah, V., Weekes, C., Diermayr, V., Ethirajulu, K., Yeo, P., Chen, D., Gan, S., Blanchard, S., Nellore, R., Lee, M.A., Hill, J., Virshup, D., Madan, B., Matter, A.
Published in Annals of oncology (01.12.2016)
Published in Annals of oncology (01.12.2016)
Get full text
Journal Article
152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours
Teneggi, V., Ng, M., Tan, D.S., Subbiah, V., Weekes, C., Diermayr, V., Ethirajulu, K., Yeo, P., Chen, D., Gan, S., Blanchard, S., Nellore, R., Lee, M.A., Hill, J., Virshup, D., Madan, B., Matter, A.
Published in Annals of oncology (01.12.2016)
Published in Annals of oncology (01.12.2016)
Get full text
Journal Article
TG02: A novel, multi-kinase inhibitor with potent activity against solid tumors
Burrows, F., Goh, K., Novotny-Diermayr, V., Hart, S., Hentze, H., Goh, M., Tan, Y., Cheetham, L., Zaknoen, S. L., Wood, J.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article